The discovery of genetic mapping led to a considerable expansion of medical data knowledge or ‘big data,’ which Foley partner Richard Kaufman suggests can be properly analyzed to improve drug discovery success and reduce the cost of developing a drug. He compares genetic mapping to an exquisite tailoring of one’s personal biology that holds the potential to make drugs developed using this data much more effective and ultimately may lead to better outcomes for patients.
People
Related News
26 April 2024
In the News
IP Laterals Ngai Zhang and Drew Schulte Make Headlines with Move to Foley
Foley & Lardner LLP partners Ngai Zhang and Drew Schulte are featured across legal press for their recent move to the firm, including in the Law360 article, “Foley & Lardner Gains Two Perkins Coie IP Partners.”
24 April 2024
In the News
Judith Waltz Discusses Nursing Home Staffing Mandate, Potential Legal Challenges
Foley & Lardner LLP partner Judith Waltz offers insight on a new nursing home staffing rule from the U.S. Department of Health and Human Services and its impact on the industry in the Bloomberg Law article, “Nursing Homes, HHS on Collision Path Over Staffing Mandate.”
23 April 2024
In the News
David Sanders Discusses Lessons Learned from General Counsel Leadership Program
Foley & Lardner LLP partner David Sanders recently joined a panel discussion with members of The Vanguard Network’s General Counsels Advisory Group to discuss the evolving role of the general counsel.